Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Indivior-Cannabis

More Like This

PR Newswire associated0

Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

PR Newswire associated0

Indivior Announces Q1 2024 Financial Results

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases

MEDICAL CANNABIS CONSORTIUM LAUNCHES FIRST MULTI-CLINIC PATIENT SURVEY OF ITS KIND